文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

机械取栓联合或不联合静脉溶栓对急性缺血性卒中功能结局的影响:SKIP随机临床试验

Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该研究为日本23家医院网络开展的多中心随机开放标签非劣效试验,纳入204例急性大血管闭塞缺血性卒中患者,比较单独机械取栓与静脉溶栓(阿替普酶0.6mg/kg)联合机械取栓的疗效。结果显示单独取栓在90天良好功能结局(mRS 0-2)方面未能证明非劣效于联合治疗,但置信区间宽,也不能得出劣效结论;单独取栓组任何颅内出血发生率更低。

要点

  • 单独机械取栓在90天良好功能结局上未证明非劣效于联合静脉溶栓,但也不能判定为劣效。
  • 单独取栓组任何颅内出血发生率显著低于联合治疗组(33.7% vs 50.5%)。
  • 两组90天死亡率及症状性颅内出血率无显著差异。

核心结论

  • 在急性大血管闭塞卒中患者中,单独机械取栓对比联合静脉溶栓加机械取栓,未能证明在良好功能结局方面非劣效,但宽置信区间也不允许得出劣效结论。

研究设计与样本

  • 由研究者发起的多中心、随机、开放标签、非劣效临床试验,在日本23家医院网络纳入204例急性大血管闭塞缺血性卒中患者。
  • 患者随机分配至单独机械取栓组(n=101)或联合静脉阿替普酶(0.6mg/kg)加机械取栓组(n=103),所有患者完成试验。

主要发现

  • 7个次要疗效终点和4个安全终点中,10个无显著差异。

关键数值与推荐

  • 静脉溶栓药物为阿替普酶,剂量0.6mg/kg。
  • 预设7个次要疗效终点(包括90天死亡率)和4个安全终点(包括36小时内任何颅内出血和症状性颅内出血)。

临床怎么用

  • 对于急性大血管闭塞卒中患者,单独机械取栓可作为联合静脉溶栓的替代选择之一,但需个体化评估,尤其关注出血风险。
  • 单独取栓与较低的 any 颅内出血风险相关,但功能结局非劣效性未确立,临床决策应结合患者具体情况。

局限性

  • 样本量较小(204例),置信区间宽,无法排除劣效或确认非劣效。
  • 开放标签设计可能引入偏倚。
  • 研究仅在日本进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether intravenous thrombolysis is needed in combination with mechanical thrombectomy in patients with acute large vessel occlusion stroke is unclear. OBJECTIVE: To examine whether mechanical thrombectomy alone is noninferior to combined intravenous thrombolysis plus mechanical thrombectomy for favorable poststroke outcome. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, multicenter, randomized, open-label, noninferiority clinical trial in 204 patients with acute ischemic stroke due to large vessel occlusion enrolled at 23 hospital networks in Japan from January 1, 2017, to July 31, 2019, with final follow-up on October 31, 2019. INTERVENTIONS: Patients were randomly assigned to mechanical thrombectomy alone (n = 101) or combined intravenous thrombolysis (alteplase at a 0.6-mg/kg dose) plus mechanical thrombectomy (n = 103). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a favorable outcome defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 2 at 90 days, with a noninferiority margin odds ratio of 0.74, assessed using a 1-sided significance threshold of .025 (97.5% CI). There were 7 prespecified secondary efficacy end points, including mortality by day 90. There were 4 prespecified safety end points, including any intracerebral hemorrhage and symptomatic intracerebral hemorrhage within 36 hours. RESULTS: Among 204 patients (median age, 74 years; 62.7% men; median National Institutes of Health Stroke Scale score, 18), all patients completed the trial. Favorable outcome occurred in 60 patients (59.4%) in the mechanical thrombectomy alone group and 59 patients (57.3%) in the combined intravenous thrombolysis plus mechanical thrombectomy group, with no significant between-group difference (difference, 2.1% [1-sided 97.5% CI, -11.4% to ∞]; odds ratio, 1.09 [1-sided 97.5% CI, 0.63 to ∞]; P = .18 for noninferiority). Among the 7 secondary efficacy end points and 4 safety end points, 10 were not significantly different, including mortality at 90 days (8 [7.9%] vs 9 [8.7%]; difference, -0.8% [95% CI, -9.5% to 7.8%]; odds ratio, 0.90 [95% CI, 0.33 to 2.43]; P > .99). Any intracerebral hemorrhage was observed less frequently in the mechanical thrombectomy alone group than in the combined group (34 [33.7%] vs 52 [50.5%]; difference, -16.8% [95% CI, -32.1% to -1.6%]; odds ratio, 0.50 [95% CI, 0.28 to 0.88]; P = .02). Symptomatic intracerebral hemorrhage was not significantly different between groups (6 [5.9%] vs 8 [7.7%]; difference, -1.8% [95% CI, -9.7% to 6.1%]; odds ratio, 0.75 [95% CI, 0.25 to 2.24]; P = .78). CONCLUSIONS AND RELEVANCE: Among patients with acute large vessel occlusion stroke, mechanical thrombectomy alone, compared with combined intravenous thrombolysis plus mechanical thrombectomy, failed to demonstrate noninferiority regarding favorable functional outcome. However, the wide confidence intervals around the effect estimate also did not allow a conclusion of inferiority. TRIAL REGISTRATION: umin.ac.jp/ctr Identifier: UMIN000021488.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Suzuki K, Matsumaru Y, Takeuchi M, et al. Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial. JAMA. 2021. PMID: 33464334. doi:10.1001/jama.2020.23522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。